Biotech Proteintech Welcomes Dr. Deepa Shankar as Chief Scientific Officer

ROSEMONT, Ill.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CSO?src=hash" target="_blank"gt;#CSOlt;/agt;–Proteintech, the benchmark in antibodies and proteins, welcomes Deepa
Shankar, PhD, as the head of global Research and Development (R&D). She
will be leading a team of over 150 scientists in the R&D and
technological operations in the company. Besides accelerating
Proteintech’s growth of their antibody and protein portfolio, she will
also oversee the technological development of its products for clinical
and pharmaceutical applications.

She comes to Proteintech with 18 years of experience in a Scientific
Director role. At Thermo Fisher Scientific, she served as Director of
R&D and Head of R&D and Manufacturing in South Asia. Prior to joining
Thermo Fisher, Dr. Shankar managed 11 oncology programs as Associate
Director of the Oncology Therapeutics Group at the drug discovery
company, Jubilant Life Sciences, in collaboration with Eli Lilly and
Company.

“Dr. Shankar’s significant experience in biotech and pharma R&D is a
great addition to our team,” says Proteintech CEO Jason Li, “Our goal is
to help scientists read the Book of Life and her leadership at
Proteintech will allow scientists all over the world to read many more
chapters.”

“I am really happy to join this organization at this exciting time. The
Company Culture is very inspiring and I am looking forward to leveraging
my past knowledge and learning from the team to fuel the forward
trajectory of the organization,” says new Proteintech CSO Deepa Shankar.

Deepa received her Ph.D. in molecular biology and immunology at the
University of Southern California in Los Angeles receiving several
awards and accolades like the Heidelberger Award for Cancer Research,
U.C. Chancellor’s research award and the Boyer-Parvin award. During her
postdoctoral work, she had opportunities to work with pharmaceutical
companies gaining exposure to clinical research industry due to her
strong passion for biology and her focus on cancer research later
developing clinically-tested disease models for leukemia. Her experience
in R&D, manufacturing, strategy and innovation will be a huge advantage
to Proteintech as it continues optimizing and expanding product lines.
An added benefit to Proteintech is her familiarity in transitional
periods and acquisition integration within a company.

About Proteintech Group

Proteintech is an antibody manufacturer selling directly to scientists
and only selling its own products to maintain the highest level of
quality control leading to superior reproducibility and lot consistency.
With over 2/3 of the human genome completed, we have a catalog of over
12,000 antibodies against 12,000 targets covering almost complete
spectrum of research areas. With its acquisition of Humanzyme,
Proteintech now offers the Humankine product line of animal-free
human-cell expressed proteins. To view tens of thousands of publications
and in-house validation images in WB, IHC, IF, FC, IP, CHIP, Knock-down
siRNA using our antibodies and to learn more about Proteintech and their
mission to deliver products directly from their bench to the
researcher’s bench, please visit www.ptglab.com.

Contacts

Proteintech Group, Inc.
Katie Bellows
[email protected]